Home > Research > Publications & Outputs > Practical implementation of the partial orderin...

Links

Text available via DOI:

View graph of relations

Practical implementation of the partial ordering continual reassessment method in a Phase I combination‐schedule dose‐finding trial

Research output: Contribution to Journal/MagazineJournal articlepeer-review

Published

Standard

Practical implementation of the partial ordering continual reassessment method in a Phase I combination‐schedule dose‐finding trial. / Mozgunov, Pavel; Jaki, Thomas; Gounaris, Ioannis et al.
In: Stat. Med., Vol. 41, No. 30, 30.12.2022, p. 5789-5809.

Research output: Contribution to Journal/MagazineJournal articlepeer-review

Harvard

APA

Vancouver

Mozgunov P, Jaki T, Gounaris I, Goddemeier T, Victor A, Grinberg M. Practical implementation of the partial ordering continual reassessment method in a Phase I combination‐schedule dose‐finding trial. Stat. Med. 2022 Dec 30;41(30):5789-5809. Epub 2022 Nov 25. doi: 10.1002/sim.9594

Author

Bibtex

@article{243380e33779402e8d041cd37fbe9caa,
title = "Practical implementation of the partial ordering continual reassessment method in a Phase I combination‐schedule dose‐finding trial",
abstract = "There is a growing medical interest in combining several agents and optimizing their dosing schedules in a single trial in order to optimize the treatment for patients. Evaluating at doses of several drugs and their scheduling in a single Phase I trial simultaneously possess a number of statistical challenges, and specialized methods to tackle these have been proposed in the literature. However, the uptake of these methods is slow and implementation examples of such advanced methods are still sparse to date. In this work, we share our experience of proposing a model‐based partial ordering continual reassessment method (POCRM) design for three‐dimensional dose‐finding in an oncology trial. In the trial, doses of two agents and the dosing schedule of one of them can be escalated/de‐escalated. We provide a step‐by‐step summary on how the POCRM design was implemented and communicated to the trial team. We proposed an approach to specify toxicity orderings and their a‐priori probabilities, and developed a number of visualization tools to communicate the statistical properties of the design. The design evaluation included both a comprehensive simulation study and considerations of the individual trial behavior. The study is now enrolling patients. We hope that sharing our experience of the successful implementation of an advanced design in practice that went through evaluations of several health authorities will facilitate a better uptake of more efficient methods in practice.",
keywords = "RESEARCH ARTICLE, RESEARCH ARTICLES, combination study, dose‐finding, dose‐schedule, partial ordering",
author = "Pavel Mozgunov and Thomas Jaki and Ioannis Gounaris and Thomas Goddemeier and Anja Victor and Marianna Grinberg",
year = "2022",
month = dec,
day = "30",
doi = "10.1002/sim.9594",
language = "English",
volume = "41",
pages = "5789--5809",
journal = "Stat. Med.",
issn = "0277-6715",
publisher = "John Wiley and Sons Ltd",
number = "30",

}

RIS

TY - JOUR

T1 - Practical implementation of the partial ordering continual reassessment method in a Phase I combination‐schedule dose‐finding trial

AU - Mozgunov, Pavel

AU - Jaki, Thomas

AU - Gounaris, Ioannis

AU - Goddemeier, Thomas

AU - Victor, Anja

AU - Grinberg, Marianna

PY - 2022/12/30

Y1 - 2022/12/30

N2 - There is a growing medical interest in combining several agents and optimizing their dosing schedules in a single trial in order to optimize the treatment for patients. Evaluating at doses of several drugs and their scheduling in a single Phase I trial simultaneously possess a number of statistical challenges, and specialized methods to tackle these have been proposed in the literature. However, the uptake of these methods is slow and implementation examples of such advanced methods are still sparse to date. In this work, we share our experience of proposing a model‐based partial ordering continual reassessment method (POCRM) design for three‐dimensional dose‐finding in an oncology trial. In the trial, doses of two agents and the dosing schedule of one of them can be escalated/de‐escalated. We provide a step‐by‐step summary on how the POCRM design was implemented and communicated to the trial team. We proposed an approach to specify toxicity orderings and their a‐priori probabilities, and developed a number of visualization tools to communicate the statistical properties of the design. The design evaluation included both a comprehensive simulation study and considerations of the individual trial behavior. The study is now enrolling patients. We hope that sharing our experience of the successful implementation of an advanced design in practice that went through evaluations of several health authorities will facilitate a better uptake of more efficient methods in practice.

AB - There is a growing medical interest in combining several agents and optimizing their dosing schedules in a single trial in order to optimize the treatment for patients. Evaluating at doses of several drugs and their scheduling in a single Phase I trial simultaneously possess a number of statistical challenges, and specialized methods to tackle these have been proposed in the literature. However, the uptake of these methods is slow and implementation examples of such advanced methods are still sparse to date. In this work, we share our experience of proposing a model‐based partial ordering continual reassessment method (POCRM) design for three‐dimensional dose‐finding in an oncology trial. In the trial, doses of two agents and the dosing schedule of one of them can be escalated/de‐escalated. We provide a step‐by‐step summary on how the POCRM design was implemented and communicated to the trial team. We proposed an approach to specify toxicity orderings and their a‐priori probabilities, and developed a number of visualization tools to communicate the statistical properties of the design. The design evaluation included both a comprehensive simulation study and considerations of the individual trial behavior. The study is now enrolling patients. We hope that sharing our experience of the successful implementation of an advanced design in practice that went through evaluations of several health authorities will facilitate a better uptake of more efficient methods in practice.

KW - RESEARCH ARTICLE

KW - RESEARCH ARTICLES

KW - combination study

KW - dose‐finding

KW - dose‐schedule

KW - partial ordering

U2 - 10.1002/sim.9594

DO - 10.1002/sim.9594

M3 - Journal article

VL - 41

SP - 5789

EP - 5809

JO - Stat. Med.

JF - Stat. Med.

SN - 0277-6715

IS - 30

ER -